Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] loss -17.16% on the last trading session, reaching $8.93 price per share at the time.
If compared to the average trading volume of 2.18M shares, MRVI reached a trading volume of 4396477 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Here is what top equities market gurus are saying about Maravai LifeSciences Holdings Inc [MRVI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRVI shares is $10.55 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRVI stock is a recommendation set at 1.58. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Craig Hallum have made an estimate for Maravai LifeSciences Holdings Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 10, 2024. While these analysts kept the previous recommendation, BofA Securities raised their target price from $10 to $8. The new note on the price target was released on December 12, 2023, representing the official price target for Maravai LifeSciences Holdings Inc stock. On May 23, 2023, analysts decreased their price target for MRVI shares from 18 to 14.
The Average True Range (ATR) for Maravai LifeSciences Holdings Inc is set at 0.60, with the Price to Sales ratio for MRVI stock in the period of the last 12 months amounting to 4.33. The Price to Book ratio for the last quarter was 2.88, with the Price to Cash per share for the same quarter was set at 4.23.
Trading performance analysis for MRVI stock
Maravai LifeSciences Holdings Inc [MRVI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.45. With this latest performance, MRVI shares gained by 13.76% in over the last four-week period, additionally plugging by 74.41% over the last 6 months – not to mention a drop of -31.57% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRVI stock in for the last two-week period is set at 39.87, with the RSI for the last a single of trading hit 29.54, and the three-weeks RSI is set at 45.85 for Maravai LifeSciences Holdings Inc [MRVI]. The present Moving Average for the last 50 days of trading for this stock 8.94, while it was recorded at 10.48 for the last single week of trading, and 7.74 for the last 200 days.
Maravai LifeSciences Holdings Inc [MRVI]: A deeper dive into fundamental analysis
Maravai LifeSciences Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.47 and a Current Ratio set at 11.32.
An analysis of Institutional ownership at Maravai LifeSciences Holdings Inc [MRVI]
The top three institutional holders of MRVI stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in MRVI stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in MRVI stock with ownership which is approximately 5.8386%.
